Global Oral Hypoglycemic Drugs Market

Oral Hypoglycemic Drugs Comprehensive Study by Drugs (Generic, Branded), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (Biguanides (Metformin), Sulfonylureas (Glimepiride), Meglitinides (Repaglinide), Thiazolidinediones (Pioglitazone), Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin), α-Glucosidase inhibitors (Acarbose)) Players and Region - Global Market Outlook to 2026

Oral Hypoglycemic Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Oral Hypoglycemic Drugs Market Overview:
According to the International Diabetes Federation estimates, the prevalence of diabetes is anticipated to escalate from 366 million in 2011 to 552 million by 2030. Statistically, approximately 80% to 90% of the patients diagnosed with hypoglycemic are also treated with obesity. Moreover, Type I and type II diabetes is expected to propel the demand for oral hypoglycemic drugs as it is a proven diabetes controller among patients globally. Oral hypoglycemic drugs are used only in the treatment of type 2 diabetes which is a disorder involving resistance to secreted insulin. Further, the rising investments on healthcare facilities have led the pharmaceutical industry to experiment with more pipeline drugs for diabetes which in turn is fostering the global oral hypoglycemic drugs market. Some of the players profiled in the study are Sanofi-Aventis (France), Eli Lilly and Company (United States), Oramed Pharmaceuticals (Israel), Takeda Pharmaceuticals Private Limited (Japan), Boehringer Ingelheim (Germany), Novo Nordisk (Denmark), Halozyme Therapeutics (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States) and Tonghua Dongbao Pharmaceutical Co., Ltd. (China).

On the basis of geography, the market of Oral Hypoglycemic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Generic will boost the Oral Hypoglycemic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Oral Hypoglycemic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Biguanides (Metformin) will boost the Oral Hypoglycemic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Prevalence of Diabetes Population among Patients
  • Rising Disposable Income and Sedentary Lifestyle of Consumers
  • Increasing Government Support and Awareness Related to Condition of Hypoglycemic

Influencing Trend
  • Introduction of new Product Launch and Commercialization of Products in the Pipeline
  • Rising Demand for Oral Drugs to Reduce Sugar Level among Hypoglycemic Population

Restraints
  • High Cost of Antidiabetic Drugs may hamper the Market Growth

Opportunities
  • High Investment in Healthcare Sector by the Government to Improve Medical Infrastructure

Challenges
  • Stringent Government Regulations and Lack of Awareness about Therapeutic Drug Treatment for Hypoglycemic


September 2017, Biocon and JDRF, a leading global organization funding Type 1 diabetes (T1D) research and advocacy worldwide, announced a partnership to support a global study with an oral insulin drug candidate, Insulin Tregopil, in people with T1D. and Insulin Tregopil, an oral insulin molecule being developed by Biocon, is one of the advanced programs in the global oral insulin space. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding a promise to transform T1D management.

January 2019, The Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration announced the benefits of Zynquista (sotagliflozin) outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor under regulatory review as an adjunct to insulin for the treatment of adults with type 1 diabetes (T1D).
The global oral hypoglycemic drugs market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.

Target Audience:
Oral Hypoglycemic Drugs Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Oral Hypoglycemic Drugs market on the basis of product [] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Oral Hypoglycemic Drugs market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Oral Hypoglycemic Drugs industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Astellas Pharma Inc.(Japan), Merck and Co.Inc.(United States) and AstraZeneca plc (United Kingdom).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Oral Hypoglycemic Drugs market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Drugs
  • Generic
  • Branded

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • Biguanides (Metformin)
  • Sulfonylureas (Glimepiride)
  • Meglitinides (Repaglinide)
  • Thiazolidinediones (Pioglitazone)
  • Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
  • α-Glucosidase inhibitors (Acarbose)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Diabetes Population among Patients
      • 3.2.2. Rising Disposable Income and Sedentary Lifestyle of Consumers
      • 3.2.3. Increasing Government Support and Awareness Related to Condition of Hypoglycemic
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations and Lack of Awareness about Therapeutic Drug Treatment for Hypoglycemic
    • 3.4. Market Trends
      • 3.4.1. Introduction of new Product Launch and Commercialization of Products in the Pipeline
      • 3.4.2. Rising Demand for Oral Drugs to Reduce Sugar Level among Hypoglycemic Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oral Hypoglycemic Drugs, by Drugs, Distribution Channel, Drug Class and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Oral Hypoglycemic Drugs (Value)
      • 5.2.1. Global Oral Hypoglycemic Drugs by: Drugs (Value)
        • 5.2.1.1. Generic
        • 5.2.1.2. Branded
      • 5.2.2. Global Oral Hypoglycemic Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Oral Hypoglycemic Drugs by: Drug Class (Value)
        • 5.2.3.1. Biguanides (Metformin)
        • 5.2.3.2. Sulfonylureas (Glimepiride)
        • 5.2.3.3. Meglitinides (Repaglinide)
        • 5.2.3.4. Thiazolidinediones (Pioglitazone)
        • 5.2.3.5. Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
        • 5.2.3.6. α-Glucosidase inhibitors (Acarbose)
      • 5.2.4. Global Oral Hypoglycemic Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Oral Hypoglycemic Drugs (Price)
  • 6. Oral Hypoglycemic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi-Aventis (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Oramed Pharmaceuticals (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceuticals Private Limited (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boehringer Ingelheim (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novo Nordisk (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Halozyme Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oral Hypoglycemic Drugs Sale, by Drugs, Distribution Channel, Drug Class and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Oral Hypoglycemic Drugs (Value)
      • 7.2.1. Global Oral Hypoglycemic Drugs by: Drugs (Value)
        • 7.2.1.1. Generic
        • 7.2.1.2. Branded
      • 7.2.2. Global Oral Hypoglycemic Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Oral Hypoglycemic Drugs by: Drug Class (Value)
        • 7.2.3.1. Biguanides (Metformin)
        • 7.2.3.2. Sulfonylureas (Glimepiride)
        • 7.2.3.3. Meglitinides (Repaglinide)
        • 7.2.3.4. Thiazolidinediones (Pioglitazone)
        • 7.2.3.5. Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin)
        • 7.2.3.6. α-Glucosidase inhibitors (Acarbose)
      • 7.2.4. Global Oral Hypoglycemic Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Oral Hypoglycemic Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oral Hypoglycemic Drugs: by Drugs(USD Million)
  • Table 2. Oral Hypoglycemic Drugs Generic , by Region USD Million (2015-2020)
  • Table 3. Oral Hypoglycemic Drugs Branded , by Region USD Million (2015-2020)
  • Table 4. Oral Hypoglycemic Drugs: by Distribution Channel(USD Million)
  • Table 5. Oral Hypoglycemic Drugs Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Oral Hypoglycemic Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Oral Hypoglycemic Drugs Online Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Oral Hypoglycemic Drugs: by Drug Class(USD Million)
  • Table 9. Oral Hypoglycemic Drugs Biguanides (Metformin) , by Region USD Million (2015-2020)
  • Table 10. Oral Hypoglycemic Drugs Sulfonylureas (Glimepiride) , by Region USD Million (2015-2020)
  • Table 11. Oral Hypoglycemic Drugs Meglitinides (Repaglinide) , by Region USD Million (2015-2020)
  • Table 12. Oral Hypoglycemic Drugs Thiazolidinediones (Pioglitazone) , by Region USD Million (2015-2020)
  • Table 13. Oral Hypoglycemic Drugs Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin) , by Region USD Million (2015-2020)
  • Table 14. Oral Hypoglycemic Drugs α-Glucosidase inhibitors (Acarbose) , by Region USD Million (2015-2020)
  • Table 15. South America Oral Hypoglycemic Drugs, by Country USD Million (2015-2020)
  • Table 16. South America Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 17. South America Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 18. South America Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 19. Brazil Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 20. Brazil Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 22. Argentina Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 23. Argentina Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 25. Rest of South America Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 26. Rest of South America Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 27. Rest of South America Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 28. Asia Pacific Oral Hypoglycemic Drugs, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 30. Asia Pacific Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 31. Asia Pacific Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 32. China Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 33. China Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 34. China Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 35. Japan Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 36. Japan Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 37. Japan Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 38. India Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 39. India Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 40. India Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 41. South Korea Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 42. South Korea Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 43. South Korea Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 44. Taiwan Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 45. Taiwan Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 46. Taiwan Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 47. Australia Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 48. Australia Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 49. Australia Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 53. Europe Oral Hypoglycemic Drugs, by Country USD Million (2015-2020)
  • Table 54. Europe Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 55. Europe Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 56. Europe Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 57. Germany Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 58. Germany Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 59. Germany Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 60. France Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 61. France Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 62. France Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 63. Italy Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 64. Italy Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 65. Italy Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 66. United Kingdom Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 67. United Kingdom Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 68. United Kingdom Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 69. Netherlands Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 70. Netherlands Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 71. Netherlands Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 72. Rest of Europe Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 73. Rest of Europe Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Europe Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 75. MEA Oral Hypoglycemic Drugs, by Country USD Million (2015-2020)
  • Table 76. MEA Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 77. MEA Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 78. MEA Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 79. Middle East Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 80. Middle East Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 81. Middle East Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 82. Africa Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 83. Africa Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 84. Africa Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 85. North America Oral Hypoglycemic Drugs, by Country USD Million (2015-2020)
  • Table 86. North America Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 87. North America Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 88. North America Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 89. United States Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 90. United States Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 91. United States Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 92. Canada Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 93. Canada Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 94. Canada Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 95. Mexico Oral Hypoglycemic Drugs, by Drugs USD Million (2015-2020)
  • Table 96. Mexico Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 97. Mexico Oral Hypoglycemic Drugs, by Drug Class USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Oral Hypoglycemic Drugs: by Drugs(USD Million)
  • Table 109. Oral Hypoglycemic Drugs Generic , by Region USD Million (2021-2026)
  • Table 110. Oral Hypoglycemic Drugs Branded , by Region USD Million (2021-2026)
  • Table 111. Oral Hypoglycemic Drugs: by Distribution Channel(USD Million)
  • Table 112. Oral Hypoglycemic Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 113. Oral Hypoglycemic Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 114. Oral Hypoglycemic Drugs Online Pharmacies , by Region USD Million (2021-2026)
  • Table 115. Oral Hypoglycemic Drugs: by Drug Class(USD Million)
  • Table 116. Oral Hypoglycemic Drugs Biguanides (Metformin) , by Region USD Million (2021-2026)
  • Table 117. Oral Hypoglycemic Drugs Sulfonylureas (Glimepiride) , by Region USD Million (2021-2026)
  • Table 118. Oral Hypoglycemic Drugs Meglitinides (Repaglinide) , by Region USD Million (2021-2026)
  • Table 119. Oral Hypoglycemic Drugs Thiazolidinediones (Pioglitazone) , by Region USD Million (2021-2026)
  • Table 120. Oral Hypoglycemic Drugs Dipeptidyl peptidase IV (DPP-IV) inhibitors (Sitagliptin) , by Region USD Million (2021-2026)
  • Table 121. Oral Hypoglycemic Drugs α-Glucosidase inhibitors (Acarbose) , by Region USD Million (2021-2026)
  • Table 122. South America Oral Hypoglycemic Drugs, by Country USD Million (2021-2026)
  • Table 123. South America Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 124. South America Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 125. South America Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 126. Brazil Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 127. Brazil Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 128. Brazil Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 129. Argentina Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 130. Argentina Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 131. Argentina Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 132. Rest of South America Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 133. Rest of South America Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 134. Rest of South America Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 135. Asia Pacific Oral Hypoglycemic Drugs, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 137. Asia Pacific Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 138. Asia Pacific Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 139. China Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 140. China Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 141. China Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 142. Japan Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 143. Japan Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 144. Japan Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 145. India Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 146. India Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 147. India Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 148. South Korea Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 149. South Korea Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 150. South Korea Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 151. Taiwan Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 152. Taiwan Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 153. Taiwan Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 154. Australia Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 155. Australia Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 156. Australia Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 160. Europe Oral Hypoglycemic Drugs, by Country USD Million (2021-2026)
  • Table 161. Europe Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 162. Europe Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 163. Europe Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 164. Germany Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 165. Germany Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 166. Germany Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 167. France Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 168. France Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 169. France Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 170. Italy Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 171. Italy Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 172. Italy Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 173. United Kingdom Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 174. United Kingdom Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 175. United Kingdom Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 176. Netherlands Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 177. Netherlands Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 178. Netherlands Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 179. Rest of Europe Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 180. Rest of Europe Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 181. Rest of Europe Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 182. MEA Oral Hypoglycemic Drugs, by Country USD Million (2021-2026)
  • Table 183. MEA Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 184. MEA Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 185. MEA Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 186. Middle East Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 187. Middle East Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 188. Middle East Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 189. Africa Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 190. Africa Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 191. Africa Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 192. North America Oral Hypoglycemic Drugs, by Country USD Million (2021-2026)
  • Table 193. North America Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 194. North America Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 195. North America Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 196. United States Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 197. United States Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 198. United States Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 199. Canada Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 200. Canada Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 201. Canada Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 202. Mexico Oral Hypoglycemic Drugs, by Drugs USD Million (2021-2026)
  • Table 203. Mexico Oral Hypoglycemic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 204. Mexico Oral Hypoglycemic Drugs, by Drug Class USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oral Hypoglycemic Drugs: by Drugs USD Million (2015-2020)
  • Figure 5. Global Oral Hypoglycemic Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Oral Hypoglycemic Drugs: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 8. Asia Pacific Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 9. Europe Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 10. MEA Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 11. North America Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 12. Global Oral Hypoglycemic Drugs share by Players 2020 (%)
  • Figure 13. Global Oral Hypoglycemic Drugs share by Players (Top 3) 2020(%)
  • Figure 14. Global Oral Hypoglycemic Drugs share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 17. Sanofi-Aventis (France) Revenue: by Geography 2020
  • Figure 18. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 20. Oramed Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Oramed Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 22. Takeda Pharmaceuticals Private Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Takeda Pharmaceuticals Private Limited (Japan) Revenue: by Geography 2020
  • Figure 24. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 26. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 27. Novo Nordisk (Denmark) Revenue: by Geography 2020
  • Figure 28. Halozyme Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Halozyme Therapeutics (United States) Revenue: by Geography 2020
  • Figure 30. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Tonghua Dongbao Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 35. Tonghua Dongbao Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 36. Global Oral Hypoglycemic Drugs: by Drugs USD Million (2021-2026)
  • Figure 37. Global Oral Hypoglycemic Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 38. Global Oral Hypoglycemic Drugs: by Drug Class USD Million (2021-2026)
  • Figure 39. South America Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 40. Asia Pacific Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 41. Europe Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 42. MEA Oral Hypoglycemic Drugs Share (%), by Country
  • Figure 43. North America Oral Hypoglycemic Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi-Aventis (France)
  • Eli Lilly and Company (United States)
  • Oramed Pharmaceuticals (Israel)
  • Takeda Pharmaceuticals Private Limited (Japan)
  • Boehringer Ingelheim (Germany)
  • Novo Nordisk (Denmark)
  • Halozyme Therapeutics (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
Additional players considered in the study are as follows:
Astellas Pharma Inc.(Japan) , Merck and Co.Inc.(United States) , AstraZeneca plc (United Kingdom)
Select User Access Type

Key Highlights of Report


Feb 2021 243 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oral Hypoglycemic Drugs Market Quantitative research analysis
Global Oral Hypoglycemic Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Oral Hypoglycemic Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Chronic Heart Failure (CHF) Drugs Comprehensive Study by Type (Anti-clotting (Aspirin), Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor), Anticoagulant Medicines (Warfarin), Blood Pres...
$ 3750
Propantheline Bromide Comprehensive Study by Application (Hyperhidrosis, Enuresis, Cramps or spasms of the stomach, Intestines or bladder), Drug type (Generic Drug, Patented Drug), Distribution Cha...
$ 3450
Lisinopril  Comprehensive Study by Patient Age (Paediatric (6 to 17 years), Adult (above 18 years)), Form (Solution, Tablet), Sales Channel (Online, Offline, Hospital Pharmacy, Retail Pharmacy), Dosa...
$ 3500
Dosulepin Comprehensive Study by Type (Tablets (75mg), Capsules (25mg)), Application (Depression Treatment, Anxiety Treatment, Others), Distribution Channel (Hospital, Drug Store, Online Store) Playe...
$ 3500
Adenovirus Vector Vaccine Comprehensive Study by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine, Others), Application (Human, Animals), ...
$ 3450
Goserelin Drug Comprehensive Study by Indication (Prostate Cancer, Breast Cancer, Endometriosis, Gynaecological Disorders), Sales Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Dose (...
$ 3500